Evidence map›Paper›PMID 24899387›Full record

SynthesisCurrent atherosclerosis reports2014

Is there sufficient enhancement of the reduction in CVD rates after a decade of statin therapy to justify continuation?

Jonathan Soverow, Karol Watson

Abstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Current atherosclerosis reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jonathan SoverowDivision of Cardiology, UCLA Medical Center, 100 UCLA Medical Plaza, Los Angeles, CA, 90095, USA, jsoverow@mednet.ucla.edu.
Karol Watson

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Randomized, controlled clinical trials have shown significant benefits of statin therapy in patients with or at risk for atherosclerotic cardiovascular disease (ASCVD). But these trials typically enroll patients for only 5 years or so, prompting some clinicians to ask what the longer term follow-up of these patients will show. While most trials have a duration of only approximately 5 years, four large trials report extended post-trial follow-up to 10 years, and these trials, as well as multiple large cohort studies, suggest an expected benefit of statins' effects beyond 10 years. In this review we will summarize the current state of the literature, the benefits noted to date, and the potentially accumulating, adverse effects of long-term statin use.

Indexed as

AtherosclerosisCardiovascular DiseasesDrug Administration ScheduleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipoproteinemia Type IIInflammationRandomized Controlled Trials as TopicRisk AssessmentTime FactorsHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.